Studies

Protocol # Short TitleTitle Target AccrualActual AccrualStatusMain EligibilityClinicalTrials.gov Link
ATN 164Screen2Prevent (S2P)Screen2Prevent (S2P): Using Digital Health to Improve HIV Screening and Prevention for Adolescents in the Emergency Department ED: 84,000 cSHS: 280PendingIn Development14-24 years of age; Able to read and understand EnglishPendinghttps://www.atnconnect.org/atn-164/
ATN 165Linking Youth to PrEP Services (LYPS)An innovative mobile delivery and mHealth intervention to optimize PrEP adherence and persistence among young gay, bisexual, and other men who have sex with men 272PendingPending13-24 years of age; Assigned male sex at birth; reports has had sex with a man in the past year; and meets CDC indications for PrEPPendinghttps://www.atnconnect.org/atn-165/
ATN 166CHOOSEAn integrated strategy of PrEP mobile health support and doxycycline PEP for young gay, bisexual, and other men who have sex with men FG: 32 Pilot: 20 RCT: 200PendingPendingFocus Groups: 13-24 years of age; Identifies as cis-gender male; Not currently taking PrEP and interested in learning more about PrEP; Self-reports being at risk for HIV acquisition, defined as having anal or vaginal sex with a cis-gender male or transgender female in the past 6 months Technical Pilot and RCT: 13-24 years of age; Identifies as cis-gender male; Not currently taking PrEP and interested in learning more about PrEP; Self-reports being at risk for HIV acquisition, defined as having anal or vaginal sex with a cis-gender male or transgender female in the past 6 months; HIV negative within 28 days of enrollment FG: NA Pilot: N/A RCT: Pendinghttps://www.atnconnect.org/atn-166/
ATN 167Legal, Economic, and Affirming Peer Support (LEAP)A status-neutral multicomponent intervention to improve HIV prevention and care continua outcomes among transgender and gender diverse youth250PendingIn Development15-24 years of age; Self-identify as a gender identity that does not correspond with the sex assigned on their original birth certificate; Self-identify as a person of color; Any condomless sex (6 months); English or Spanish speakingPendinghttps://www.atnconnect.org/atn-167/
ATN 168HIV and Pregnancy Protection in Youth (HAPPY)Values and Preferences for a Novel, Systemic, Injectable Multipurpose Product for HIV and Pregnancy Prevention in Individuals Assigned Female at Birth in the United States IDI: 50 Pilot: 15 DCE: 440IDI: 38Enrolling15-24 years of age; Assigned female at birth; NAhttps://www.atnconnect.org/atn-168/
ATN 169LEN BRIDGESafety, Tolerability, Acceptability and Pharmacokinetics of Novel, Long-Acting Injectable Lenacapavir for the Prevention of HIV among Adolescents60PendingProtocol Development Paused13-17 years of age; Assigned female, male or intersex at birth and self-identify as either cisgender or transgender; Sexually active (in the last 12 months) with at least one partner assigned male at birth; Body weight ≥ 35 kg; Able to read and understand EnglishPendinghttps://www.atnconnect.org/atn-coming-soon/
ATN 170IMPACTHybrid Type 2 Effectiveness-Implementation Trial of Status Neutral, Integrated Behavioral Activation and Risk Reduction Intervention for Stimulant Use Among Sexually Active Young GBMSM 360PendingPending15-24 years of age at enrollment; Self-identifies as cisgender boy or man; Resides in United States; Self-report CAS with another boy/man – receptive or insertive – while using stimulants (1 hour prior to, or during, sex) within the last 3 monthsPendinghttps://www.atnconnect.org/atn-170/
ATN 172MPTDeveloping a Novel, Multipurpose Injectable Product Containing Cabotegravir (CAB) and Levonorgestrel (LNG) for Healthy, HIV-Negative Youth Assigned Female at Birth (AFAB) in the United States (US), including Transgender and Gender Diverse (TGD) Youth16PendingNot Yet In DevelopmentHealthy, HIV-negative adolescents and young adults AFAB, ages 18-24 years, inclusivePendinghttps://www.atnconnect.org/atn-coming-soon/

Abbreviations:
cSHS = Computerized Sexual Health Screen; DCE = Discrete Choice Experiment; ED = Emergency Department; FG = Focus Group; IDI = In Depth Interview; RCT = Randomized Clinical Trial